Addex Pharma S.A.
8
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
37.5%
3 terminated/withdrawn out of 8 trials
62.5%
-24.0% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
Role: lead
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Role: lead
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
Role: lead
PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration
Role: collaborator
ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease
Role: lead
ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
Role: lead
ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)
Role: lead
ADX10059 Migraine Prevention Study
Role: lead
All 8 trials loaded